Journal articles: 'Non-invasive ventilation therapy'

1

Mehta, Akshay. "Synopsis on Non-invasive Ventilation in Neonatology." International Journal of Clinical Case Reports and Reviews 7, no. 04 (July 17, 2021): 01–06. http://dx.doi.org/10.31579/2690-4861/128.

Full text

Abstract:

Non-invasive ventilation (NIV) is a mode of respiratory support commonly used on the neonatal unit. Since the advent of NIV, it has evolved from being used as a mode of respiratory support to wean infants from mechanical ventilation (MV) to a primary mode of respiratory support. NIV improve the functional residual capacity in the newborn (at term or preterm) avoiding invasive actions such as tracheal intubation. Newer methods of NIV support such as nasal bilevel positive airway pressure (BiPAP) and humidified high flow nasal cannula oxygen therapy (HHFNC) have emerged in attempts to reduce intubation rates and subsequent MV in preterm infants. With this synopsis, we aim to discuss various available NIV modes of ventilation in Neonatology, including indications, physiological principle, practical aspects and effects on important short and long-term morbidities associated with the use of NIV.

APA, Harvard, Vancouver, ISO, and other styles

2

Аvdeev, S. N. "AEROSOL THERAPY DURING NON-INVASIVE VENTILATION." Messenger of ANESTHESIOLOGY AND RESUSCITATION 15, no. 2 (May 23, 2018): 45–54. http://dx.doi.org/10.21292/2078-5658-2018-15-2-45-54.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

White, Victoria. "Non-invasive Ventilation in Acute Respiratory Failure." Physiotherapy 86, no. 4 (April 2000): 221. http://dx.doi.org/10.1016/s0031-9406(05)60979-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nizami, Mohammed Ismail, Narendra Kumar N., Ashima Sharma, G. Vishwa Reddy, and S. Raghavendra Goud. "Non-Invasive Ventilation: First Line Therapy in the Acute Exacerbations of COPD in Emergency Department." Indian Journal of Emergency Medicine 3, no. 2 (2017): 217–22. http://dx.doi.org/10.21088/ijem.2395.311x.3217.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Wood, C., S. Aristobil-Adele, J. Wittwer, K. Gray, and K. Waters. "P140 Non-invasive Ventilation prior to Adenotonsillectomy." SLEEP Advances 3, Supplement_1 (October 1, 2022): A74—A75. http://dx.doi.org/10.1093/sleepadvances/zpac029.208.

Full text

Abstract:

Abstract Introduction Prolonged wait times to ENT surgery, combined with the risk for post-operative respiratory events in children with severe OSA led to a clinical pathway of implementing CPAP therapy in children with severe OSA whilst on waiting lists for adenotonsillectomy. This study evaluated the impact of this pathway on the clinical care of these patients. Methods A retrospective review of medical records of patients under 18yrs of age diagnosed with OSA and initiated on CPAP whilst awaiting review by ENT / Adenotonsillectomy, between January 2019 and December 2020. Results 36 patients were identified, age 4.3 ± 3.2 years, 86% male, and 80.6% had comorbidities. 16 (44.4%) were overweight or obese, and for 8 (22.2%) obesity was the primary comorbidity. Mean delays: Sleep study to Referral = 4.5 ± 10.5 weeks, Referral to NIV initiation 5.6 ± 8.7 weeks, and NIV to ENT surgery 13.6 ± 13.6 weeks. Total delay from referral to the surgery was 19.6 ± 19.4 weeks. 31 (86%) children were initiated on therapy in hospital, and five (13.9%) patients were non-compliant with the therapy. Discussion Current delays to ENT surgery for children identified with OSA on sleep study average 5 months. Where OSA is sufficient to recommend ENT surgery, the majority (80%) of children tolerated CPAP therapy while they await surgery. We suggest that the benefits obtained are that therapy can be instituted more rapidly than surgery, and where children are able to use CPAP therapy it reduced the requirement for high-dependency or intensive care admission post-operatively.

APA, Harvard, Vancouver, ISO, and other styles

6

Ciobanu, Laura. "Is there enough room for non-invasive ventilation in pulmonary rehabilitation?" Biotechnology and Bioprocessing 1, no. 2 (December 10, 2020): 01–06. http://dx.doi.org/10.31579/2766-2314/007.

Full text

Abstract:

Pulmonary rehabilitation (PR) is a non-pharmacological intervention addressed to chronic obstructive pulmonary disease (COPD) and non-COPD chronic respiratory patients, a key management strategy scientifically demonstrated to improve exercise capacity, dyspnoea, health status and psychological wellbeing. The main body of literature comes from COPD patients, as they provide the core evidence for PR programmes. PR is recommended even to severe patients having chronic respiratory failure; their significant psychological impairment and potential for greater instability during the PR programme will be carefully considered by the multidisciplinary team. Optimizing medical management (e g, inhaled bronchodilators, oxygen therapy, non- invasive ventilation) may enhance the results of exercise training. Patients who already receive long-term domiciliary non- invasive ventilation (NIV) for chronic respiratory failure might exercise with NIV during exercise training if acceptable and tolerable to the patient. It is not advisable to offer long-term domiciliary NIV with the only aim to improve outcomes during PR course. There are different attempts to use both negative and positive NIV in limited clinical studies. Long-term adherence to exercise is an important goal of PR programmes and teams, targeting to translate all-domain gains of PR into increased physical activity and participation to real life. Being a reliable alternative for the future, studies should focus on pressure regimens, type of devices, acceptability and portability for everyday activities.

APA, Harvard, Vancouver, ISO, and other styles

7

Rauf-ul-Hassan, Muahmmad, Ahtesham Iqbal, Muhammad Waseem, Muhammad Zubair Ashraf, Tehreem Abaid, and Anam Saleem. "Non-Invasive Ventilation versus Invasive Mechanical Ventilation: Results from a Tertiary Care Hospital." Pakistan Journal of Medical and Health Sciences 16, no. 1 (January 18, 2022): 256–58. http://dx.doi.org/10.53350/pjmhs22161256.

Full text

Abstract:

Objective: To compare the patient outcome in severe COVID-19 pneumonia between the non-invasive ventilation and invasive mechanical ventilation. Study design: Prospective, observational study Study Setting and Duration: Department of Pulmonology, Bahawal Victoria Hospital, Bahawalpur from January 2021 to June 2021. Methodology: We analyzed 660 patients of severe covid pneumonia. Conscious proning was done in those requiring ≥ 21 L oxygen and oxygen saturation < 90%. We defined typical ARDS according to Berlin criteria. Atypical ARDS did not fulfill set criteria. We divided ARDS into 2 types i-e H and L type. We managed ARDS with either NIV, invasive mechanical ventilation or both. We used multiple regression analysis to predict ICU stay. Results: Out of 660 patients, 285 (43.18%) developed biPAP failure and were subsequently intubated. We observed 273 (41.4%) overall mortality, 175 (64.1%) in IMV and 98 (35.9%) in the NIV group (p<0.0001). invasive mechanical ventilation had statistically significant correlation with mortality and also predicted ICU stay. (p=< 0.001, OR 3.2, p=0.001). Conclusion: NIV therapy is superior to invasive mechanical ventilation in terms of ICU stay and outcome. Keywords: ARDS, coronavirus, COVID-19, non-invasive ventilation, mechanical ventilation, pneumonia

APA, Harvard, Vancouver, ISO, and other styles

8

Majid, Norhaini, Roswati Nordin, Norshamatul Aidah Osran, and Suryanto Suryanto. "Helmet Non-invasive Ventilation Therapy: Measurement of comfort behaviour." Environment-Behaviour Proceedings Journal 6, no. 18 (December 12, 2021): 119–24. http://dx.doi.org/10.21834/ebpj.v6i18.3082.

Full text

Abstract:

Comfort is integral towards tolerance in helmet non-invasive ventilation (NIV) therapy among acute respiratory failure (ARF) patients. This study aims to measure the patients’ comfort behaviour level after completion of helmet NIV therapy. It is a quantitative, descriptive, observational study involving 67 ARF patients. Kolcaba's Comfort Behavioural Checklist (CBC) was used, with the highest score of 120. The mean CBC score was 88.54, SD 7.35, indicating moderate comfort level; for Acute Pulmonary Oedema (APO) and non- APO, patients were 89.88, SD 7.25, and 87.08, SD 7.80 respectively. This reflects genuine patients' response towards therapy which is significant for future improvement. Keywords: Helmet Continuous Positive Airway Pressure; CPAP; Kolcaba’s Behavioural Checklist; Acute Respiratory Failure eISSN: 2398-4287© 2021. The Authors. Published for AMER ABRA cE-Bs by e-International Publishing House, Ltd., UK. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Peer–review under responsibility of AMER (Association of Malaysian Environment-Behaviour Researchers), ABRA (Association of Behavioural Researchers on Asians/Africans/Arabians) and cE-Bs (Centre for Environment-Behaviour Studies), Faculty of Architecture, Planning & Surveying, Universiti Teknologi MARA, Malaysia. DOI: https://doi.org/10.21834/ebpj.v6i18.3082

APA, Harvard, Vancouver, ISO, and other styles

9

Brigg, Craig. "The benefits of non-invasive ventilation and CPAP therapy." British Journal of Nursing 8, no. 20 (November 11, 1999): 1355–61. http://dx.doi.org/10.12968/bjon.1999.8.20.1355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tsygankov, К. A., I. N. Grachev, Vladimir I. Shatalov, А. V. Schegolev, D. A. Аveryanov, R. S. Lakotko, and М. А. Karnaushkina. "The impact of non-invasive respiratory support techniques on the lethal outcome frequency in adult with severe respiratory failure caused by the new coronavirus infection." Messenger of ANESTHESIOLOGY AND RESUSCITATION 18, no. 1 (March 6, 2021): 47–56. http://dx.doi.org/10.21292/2078-5658-2021-18-1-47-56.

Full text

Abstract:

The objective: to evaluate the effect of high-flow oxygen and non-invasive ventilation on the mortality rate in adults with severe respiratory failure caused by the new coronavirus infection in the intensive care unit (ICU).Subjects and methods. A one-center retrospective study was conducted. Electronic medical files of patients treated in the ICU from April 1 to May 25, 2020, were analyzed. Totally, 101 medical files were selected, further, they were divided into two groups. Group 1 (n = 49) included patients who received oxygen insufflation, and should it fail, they received traditional artificial ventilation. No non-invasive respiratory therapy was used in this group. Group 2 (n = 52) included patients who received high-flow oxygen therapy and non-invasive ventilation. The mortality rate in the groups made a primary endpoint for assessing the impact of high-flow oxygen therapy and non-invasive ventilation. The following parameters were also analyzed: drug therapy, the number of patients in whom non-invasive techniques were used taking into account the frequency of cases when these techniques failed, and the number of patients in whom artificial ventilation was initiated.Results. In Group 2, non-invasive methods of respiratory therapy were used in 31 (60%) cases. High-flow oxygen therapy was used in 19 (36%) of them; in 13 cases this method allowed weaning them from the high flow. Non-invasive ventilation was used in 18 cases, in 12 patients it was used due to progressing severe respiratory failure during humidified oxygen insufflation, in 6 patients – after the failed high-flow oxygen therapy. In Group 1, 25 (51%) patients were intubated and transferred to artificial ventilation, in Group 2, 10 (19.2%) underwent the same. The lethal outcome was registered in 23 (47%) cases in Group 1, and in 10 (19.2%) in Group 2 (p = 0.004). Analysis of drug therapy in the groups revealed the difference in the prescription of pathogenetic therapy. Logistic regression demonstrated the effectiveness of the combination of tocilizumab + a glucocorticoid in reducing the frequency of lethal cases (p = 0.001).Conclusion. The use of non-invasive respiratory support in adults with severe respiratory failure caused by the new coronavirus infection combined with therapy by tocilizumab + a glucocorticoid can reduce the incidence of lethal cases.

APA, Harvard, Vancouver, ISO, and other styles

11

Idil, Hasan, and Orkun Unek. "Non-Invasive CPAP Ventilation in Acute Carbon Monoxide Poisoning." Prehospital and Disaster Medicine 34, no. 04 (June 26, 2019): 454–55. http://dx.doi.org/10.1017/s1049023x19004485.

Full text

Abstract:

AbstractOxygen is the main treatment of carbon monoxide (CO) poisoning. In two simultaneous cases, the efficacy of conventional and continuous positive airway pressure (CPAP)-administered oxygen therapy was compared. A 63-year-old man and his 58-year-old wife were brought to the emergency department with complaints of dizziness, headache, and nausea. The man had a history of congestive heart failure and additionally had shortness of breath. Initial carboxyhemoglobin (COHb) values were 26% in the male patient and 24% in his wife. For the female patient, oxygen therapy was performed with a reservoir balloon mask; a CPAP device was used for the male patient. The COHb levels decreased below five percent after approximately two hours in the male patient and at the end of five hours in his wife. In follow-up, symptomatic relief was achieved in both patients and no additional complications were observed. According to our experience, CPAP ventilation can be a new and effective method for oxygen therapy in CO poisoning.

APA, Harvard, Vancouver, ISO, and other styles

12

Filyk, Olha. "Non-Invasive Mechanical Ventilation in Children with Previous Unsuccessful Weaning from Respiratory Therapy." Galician Medical Journal 27, no. 3 (September 28, 2020): E2020311. http://dx.doi.org/10.21802/gmj.2020.3.11.

Full text

Abstract:

The objective of the research was to establish the impact of diaphragm-protective mechanical ventilation on the rate of successful weaning from invasive and non-invasive mechanical ventilation in children with acute respiratory failure. Materials and Methods. We conducted a prospective, observational cohort study. Seventy-eight patients were randomly divided into 2 groups: patients of Group I received lung-protective mechanical ventilation; patients of Group II received diaphragm-protective + lung-protective mechanical ventilation. For age-specific data analysis, patients were divided into age subgroups: the 1st subgroup included children being 1 to 12 months old; the 2nd age subgroup comprised children being 12 to 36 months old. We started respiratory support in both groups with invasive mechanical ventilation and when patients met the criteria, we weaned them. We confirmed successful weaning, when patients had no need to be mechanically ventilated within next 48 hours, otherwise, they were intubated again. Before the second trial to wean, patients in Group I were simply extubated, while patients in Group II received non-invasive mechanical ventilation. The primary endpoint was the rate of successful weaning from mechanical ventilation in the first trial. The secondary outcomes were complications, namely reintubation rate, tracheostomy rate and death. Results. We found a significant difference in the primary outcome for the 1st age subgroup: there were 72.4% in Group I vs. 52.6% in Group II successfully weaned patients (p=0.04). No significant difference in the primary outcome was observed in the 2nd age subgroup: there were 80% in Group I vs. 82.3% in Group II successfully weaned patients (p=0.78). There were significant differences in the secondary outcomes between groups in the 1st age subgroup, namely reintubation rate was seen in 9.1% patients of Group I vs. 36.8% patients of Group II (p=0.05); death happened in 18.2% cases in Group I vs. no cases in Group II (p=0.01). There were no differences in tracheostomy rate in the 1st age subgroup and there were no differences in the secondary outcomes between groups in 2nd age subgroup. Conclusions. Diaphragm-protective mechanical ventilation significantly reduced the incidence of successful weaning from invasive mechanical ventilation; however, it increased the incidence of successful weaning from non-invasive mechanical ventilation, and, significantly decreased the mortality rate in the 1st age subgroup, while in the 2nd age subgroup, it had no impact on the incidence of successful weaning from invasive mechanical ventilation and mortality rate.

APA, Harvard, Vancouver, ISO, and other styles

13

Fitzgerald, Dominic A. "Weaning long term non-invasive ventilation (NIV) therapy in children." Pediatric Pulmonology 52, no. 12 (October 24, 2017): 1529–30. http://dx.doi.org/10.1002/ppul.23888.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Esquinas, A. M., and H. M. R. Karim. "Physiotherapist-administered non-invasive ventilation to reduce postoperative pulmonary complications." Physiotherapy 107 (June 2020): 327. http://dx.doi.org/10.1016/j.physio.2019.05.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Rodriguez Hortal, Maria Cecilia, Malin Nygren-Bonnier, and Lena Hjelte. "Non-invasive Ventilation as Airway Clearance Technique in Cystic Fibrosis." Physiotherapy Research International 22, no. 3 (February 29, 2016): e1667. http://dx.doi.org/10.1002/pri.1667.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Oinotkinova, O. Sh, S. V. Stebletsov, O. M. Maslennikova, A. S. Zakirova, and O. V. Pashovkina. "Clinical aspects of using non-invasive nasal ventilation in patients after COVID-19 complicated by bilateral multisegmental pneumonia." Academy of medicine and sports 2, no. 4 (January 20, 2022): 12–19. http://dx.doi.org/10.15829/2712-7567-2021-40.

Full text

Abstract:

A clinical experience of using non-invasive nasal ventilation in patients after coronavirus disease 2019 (COVID-19) complicated by bilateral multisegmental pneumonia. It has been shown that, against the background of medication therapy, there is a restoration of ventilation-perfusion relationships in lung atelectasis areas, which is confirmed by spirometry and chest computed tomography. Implementation of non-invasive nasal ventilation against the background of drug therapy to restructure diffuse pulmonary fibrosis allows to accelerate the onset of dynamic exercise due to improved exercise tolerance.

APA, Harvard, Vancouver, ISO, and other styles

17

Hassan, Taimoor, Sana Saeed, Sidra Naseem, and Fiza Saleem. "INTENSIVE CARE UNIT MANAGEMENT OF SARS-COV-2 PATIENTS: A NARRATIVE REVIEW." Gomal Journal of Medical Sciences 19, no. 4 (December 31, 2021): 152–56. http://dx.doi.org/10.46903/gjms/19.04.1024.

Full text

Abstract:

The 2019 Coronavirus disease is a public health emergency of international concern (PHEIC). COVID-19 causes acute respiratory distress syndrome (ARDS) in certain individuals. In such individuals, non-invasive and invasive ventilation methods are used to treat acute respiratory distress syndrome. Non-invasive ventilation approaches must be used initially before introducing intrusive mechanical ventilation techniques. Non-invasive methods used in the therapy of COVID -19 associated acute respiratory syndrome include high-flow nasal cannula, bi-level positive air pressure (BiPAP), and helmet ventilation. Before employing any of these non-invasive methods, the risk of viral aerosol transmission to healthcare and paramedical personnel must be considered. When non-invasive procedures are used, the load on hospital ventilatory equipment can be reduced. If at all possible, avoid intubating the patient too soon. The clinical appearance of the patient, as well as vital indicators such as oxygen saturation and respiratory rate, must be evaluated on a frequent basis in order to determine whether the patient requires ventilation. In COVID-19 patients, the judicious application of non-invasive and invasive breathing methods can minimize the risk of death from acute respiratory distress syndrome.

APA, Harvard, Vancouver, ISO, and other styles

18

Raju, Bhavani Mohan, Sushma Jotkar, Prathyusha M., Shraddha Goswami, Mukesh Dube, and Abhishek Singh. "Effectiveness of non-invasive positive pressure ventilation for acute exacerbation of chronic obstructive pulmonary disease." International Journal of Clinical Trials 5, no. 2 (April 24, 2018): 102. http://dx.doi.org/10.18203/2349-3259.ijct20181740.

Full text

Abstract:

Background: In patients with acute exacerbations of COPD, endotracheal intubation and complications associated with mechanical ventilation may be evaded using non-invasive ventilation. The aim of the study was to analyse the effectiveness of NPPV for hypercapnic respiratory failure secondary to acute exacerbation of COPD in India.Methods: In this prospective study, 63 cases of hypercapnic respiratory failure secondary to acute exacerbation of COPD admitted in the intensive care unit during 2011-13 formed the study population. Standard therapy was initiated in all the patients. Patients who failed to improve with standard therapy alone were given a trial of non invasive ventilation. Non invasively ventilated patients, showing significantly improvement in their clinical status and arterial blood gas parameters were discharged. Patients who failed to show significant improvement with NPPV were given invasive ventilation.Results: Standard therapy was initiated in 63 patients on admission but 25 patients failed to improve with standard therapy alone. Out of the total 25 patients non invasively ventilated, 22 patients showed significantly improvement. Significant improvement in the Mean pH, Mean paCO2 and Mean paHCO3 in both standard therapy and non invasive ventilation group. Success rate was found to be highest (88%) in standard therapy + noninvasive ventilation treatment modality group.Conclusions: NIV is an effective tool in hypercapnic respiratory failure secondary to acute exacerbation of COPD and its early initiation would improve the clinical status and respiratory acidosis.

APA, Harvard, Vancouver, ISO, and other styles

19

Maia, Israel S., Leticia Kawano-Dourado, Fernando G. Zampieri, Lucas P. Damiani, Renato H. Nakagawa, Rodrigo M. Gurgel, Karina Negrelli, et al. "High flow nasal catheter therapy versus non-invasive positive pressure ventilation in acute respiratory failure (RENOVATE trial): protocol and statistical analysis plan." Critical Care and Resuscitation 24, no. 1 (March 7, 2022): 61–70. http://dx.doi.org/10.51893/2022.1.oa8.

Full text

Abstract:

BACKGROUND: The best way to offer non-invasive respiratory support across several aetiologies of acute respiratory failure (ARF) is presently unclear. Both high flow nasal catheter (HFNC) therapy and non-invasive positive pressure ventilation (NIPPV) may improve outcomes in critically ill patients by avoiding the need for invasive mechanical ventilation (IMV). OBJECTIVE: Describe the details of the protocol and statistical analysis plan designed to test whether HFNC therapy is non-inferior or even superior to NIPPV in patients with ARF due to different aetiologies. METHODS: RENOVATE is a multicentre adaptive randomised controlled trial that is recruiting patients from adult emergency departments, wards and intensive care units (ICUs). It takes advantage of an adaptive Bayesian framework to assess the effectiveness of HFNC therapy versus NIPPV in four subgroups of ARF (hypoxaemic non-immunocompromised, hypoxaemic immunocompromised, chronic obstructive pulmonary disease exacerbations, and acute cardiogenic pulmonary oedema). The study will report the posterior probabilities of non-inferiority, superiority or futility for the comparison between HFNC therapy and NIPPV. The study assumes neutral priors and the final sample size is not fixed. The final sample size will be determined by a priori determined stopping rules for non-inferiority, superiority and futility for each subgroup or by reaching the maximum of 2000 patients. OUTCOMES: The primary endpoint is endotracheal intubation or death within 7 days. Secondary outcomes are 28-day and 90-day mortality, and ICU-free and IMV-free days in the first 28 days. RESULTS AND CONCLUSIONS: RENOVATE is designed to provide evidence on whether HFNC therapy improves, compared with NIPPV, important patient-centred outcomes in different aetiologies of ARF. Here, we describe the rationale, design and status of the trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03643939.

APA, Harvard, Vancouver, ISO, and other styles

20

Eva Marti. "Penggunaan Ventilasi Mekanik non Invansif Untuk Mengatasi Kegagalan Pernafasan pada Pasien dengan Edema Pulmo Akut Kardiogenik." I Care Jurnal Keperawatan STIKes Panti Rapih 1, no. 2 (October 23, 2020): 91–100. http://dx.doi.org/10.46668/jurkes.v1i2.86.

Full text

Abstract:

Background: Cardiogenic Pulmo edema can cause a heterogeneous syndrome with a mortality rate of up to 9.5% (Aliberti et all., 2018).Objective: The purpose of this paper was to explain how effective the use of non-invasive mechanical ventilation in patients with acute pulmonary edema with respiratory failure. Methods: The literature review was compiled by synthesizing and comparing various relevant scientific articles from the literature search results using the online database of Proquest and Clinicalkey Elsevier that have significance related to the management of acute cardiogenic pulmo edema. Result: Compared with conservative therapy, noninvasive mechanical ventilation has been shown more effective in improving oxygenation in patients with acute cardiogenic pulmo edema Non-invasive ventilation can reduce dyspnea, acidosis and hypercapnea faster than standard oxygen therapy. Studies show that compared to endotracheal intubation, non-invasive mechanical ventilation is associated with a lower risk of nosocomial infection, lower antibiotic use, shorter length of stay in intensive care units and lower mortality. Study found that there were no differences betwen the two setting of non-invasive mechanical ventilation used, Bilevel positive Airway Pressure (BiPAP) and Continues positive Airway Pressure (CPAP) in patients outcomes. However, there are absolute and relative contraindications that must be considered, including the effectiveness of the therapy being insignificant when given too late Conclusion: Noninvasive mechanical ventilation can be considered as the first choice in the management of acute cardiogenic pulmonary edema because of its high clinical effectiveness representing a rescue action for patients not improving with conventional oxygen therapy.

APA, Harvard, Vancouver, ISO, and other styles

21

Hailu, Michael T., Kaleab D. Workagegnehu, and Adarsh Manoj. "Outcomes in neonates with respiratory distress syndrome using Saana non-invasive ventilation." International Journal Of Community Medicine And Public Health 9, no. 8 (July 27, 2022): 3209. http://dx.doi.org/10.18203/2394-6040.ijcmph20222025.

Full text

Abstract:

Background: In low-and-middle income countries (LMICs), neonatal mortality is still unacceptably high compared to developed nations. Respiratory distress syndrome (RDS) is one of the major contributors to high mortality rates in this population. This study was conducted to analyze the effects of Saans non-invasive ventilation (NIV), an infrastructure-independent continuous positive airway pressure (CPAP) and resuscitation device, on neonatal mortality and cost compared to current practices.Methods: This single-center, prospective, observational analytical study was to determine the efficacy of Saans NIV in delivering CPAP and resuscitation therapy to neonates diagnosed with RDS.Results: An 82% success rate was recorded while using Saans NIV for CPAP and resuscitation therapy in this study, which was far superior to the global average. This also means that 82% of the patients included in this study avoided invasive mechanical ventilation. After a cost analysis, we concluded that invasive mechanical ventilation would cost $3478 USD for treatment vs. just $155 USD for patients treated with traditional CPAP therapy.Conclusions: Infrastructure-independent devices such as Saans NIV are game-changers in LMICs. Saans NIV makes CPAP and safe resuscitation therapy available in resource-constrained settings and during transport. This study showcases that Saans NIV can significantly reduce the need for invasive mechanical ventilation and the costs associated with treating neonates.

APA, Harvard, Vancouver, ISO, and other styles

22

Sundling, Ing-Mari, Sirkka-Liisa Ekman, Jan Weinberg, and Brita Klefbeck. "Patients’ with ALS and caregivers’ experiences of non-invasive home ventilation." Advances in Physiotherapy 11, no. 3 (January 2009): 114–20. http://dx.doi.org/10.1080/14038190701803351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Thein, Onn Shaun, Muhammad Niazi, Abdisamad Ali, and Adeel Sahal. "Pneumomediastinum in patients with SARS-CoV-2 treated with non-invasive ventilation." BMJ Case Reports 14, no. 3 (March 2021): e241809. http://dx.doi.org/10.1136/bcr-2021-241809.

Full text

Abstract:

SARS-CoV-2, causing the pandemic COVID-19, has rapidly spread, overwhelming healthcare systems. Non-invasive positive pressure ventilation (NIV) can be used as a bridging therapy to delay invasive mechanical ventilation or as a standalone therapy. Spontaneous pneumomediastinum is rare and self-limiting, but there is an increased incidence documented in COVID-19.Here we document two cases of pneumomediastinum-related prolonged NIV therapy in severe COVID-19. Patient 1, a 64-year-old man, who developed symptoms after NIV therapy was weaned and survived. Patient 2, an 82-year-old woman, failed to improve despite NIV therapy, on investigation was found to have a pneumomediastinum. After review, the patient was placed on best supportive care and died 3 days later.We highlight the importance of recognising less common causes of deterioration in severe COVID-19 treated with NIV. In addition, pneumomediastinum in these cases may not always lead to poor outcomes.

APA, Harvard, Vancouver, ISO, and other styles

24

Parente, Karla Aires, Rafaela Rosa Ferreira, and Karla Camila Correia da Silva. "Non invasive ventilation and the high-flow nasal circuit." Research, Society and Development 12, no. 1 (January 5, 2023): e14312139636. http://dx.doi.org/10.33448/rsd-v12i1.39636.

Full text

Abstract:

The purpose of this study is to discuss non-invasive ventilation and the High Flow Nasal Circuit (HFNC). The therapy is used by intensivists in Intensive Care Units – ICUs. It is a non-invasive breathing support modality that delivers heated and humidified gas mixtures to bedridden patients through a nasal cannula. The methodology used for the theme occurred in the online databases, Virtual Health Library (VHL) and Scientific Electronic Library Online (SCIELO). For greater reliability of the articles, a bibliographical survey of relevant studies was carried out, using keywords on the subject, and the selected articles had as criteria: clinical studies published in the last ten years. this new technique as a means of non-invasive ventilatory support, aims to provide the patient with greater comfort, improved oxygenation, reduced need for invasive mechanical ventilation and reduced reintubation rates. Because it is a new alternative, new studies must be carried out in the scientific academy.

APA, Harvard, Vancouver, ISO, and other styles

25

Yuval, Cavari, Shlomo Tal Levy, Neeman Eitan, Taragin Ben, Leder Michal, Yarza Shaked, and Lazar Isaac. "Intrapulmonary percussive ventilation for children with bronchiolitis on non-Invasive Ventilation support." Open Journal of Pediatrics and Child Health 7, no. 1 (November 1, 2022): 025–30. http://dx.doi.org/10.17352/ojpch.000042.

Full text

Abstract:

Objective: Pediatric Intensive Care (PICU) admission of children with bronchiolitis as well as the use of Non-Invasive Ventilation (NIV) are increasing. The current treatment for bronchiolitis is supportive, and there are no specific studies addressing this group of severe bronchiolitis patients supported with NIV. Intrapulmonary Percussive Ventilation (IPV) is a lung recruitment physical therapy technique used in our PICU to augment lung aeration and improve gas exchange. We hypothesized that IPV treatment can be used to improve the clinical course of infants on NIV support suffering from bronchiolitis. Design: A prospective, open, randomized study. Setting: Single-center Pediatric ICU Patients: Children less than 2 years old admitted to our PICU between November 2016 and April 2018 with a diagnosis of bronchiolitis who were prescribed noninvasive positive pressure ventilation as their sole respiratory treatment modality Interventions: Patients were randomly assigned to two intervention groups: IPV vs. control (standard treatment). Measurements and main results: Thirty-eight infants with bronchiolitis treated with NIV support were randomized into two groups. The probability of a superior outcome (less chance of invasive mechanical ventilation and fewer PICU days) was 62.7% (95% CI, 45%-77%, p = 0.18) in the IPV group compared to the control group. Among the IPV group, there were no failures that required intubation in comparison to three intubations (13.6%) among the control group (p = 0.24). For the IPV group, the PICU length of stay (LOS) was 4.13 ± 2.45 days, compared to 6.18 ± 4.72 for the inhalation group. This difference was not statistically significant. Conclusions: In this single-center study, the use of IPV had no adverse reactions. The study failed to show a statistically significant effect of IPV treatment on the course of hospitalization of patients with bronchiolitis on NIV support in the PICU. Trial registration: Clinical Trials.gov NCT03037801.

APA, Harvard, Vancouver, ISO, and other styles

26

Boots, R. J., J. Lipman, R. Bellomo, D. Stephens, and R. F. Heller. "Disease Risk and Mortality Prediction in Intensive Care Patients with Pneumonia. Australian and New Zealand Practice in Intensive Care (ANZPIC II)." Anaesthesia and Intensive Care 33, no. 1 (February 2005): 101–11. http://dx.doi.org/10.1177/0310057x0503300116.

Full text

Abstract:

This study of ventilated patients investigated pneumonia risk factors and outcome predictors in 476 episodes of pneumonia (48% community-acquired pneumonia, 24% hospital-acquired pneumonia, 28% ventilator-associated pneumonia) using a prospective survey in 14 intensive care units within Australia and New Zealand. For community acquired pneumonia, mortality increased with immunosuppression (OR 5.32, CI 95% 1.58–17.99, P<0.01), clinical signs of consolidation (OR 2.43, CI 95% 1.09–5.44, P=0.03) and Sepsis-Related Organ Failure Assessment (SOFA) scores (OR 1.19, CI 95% 1.08–1.30, P<0.001) but improved if appropriate antibiotic changes were made within three days of intensive care unit admission (OR 0.42, CI 95% 0.20–0.86, P=0.02). For hospital-acquired pneumonia, immunosuppression (OR 6.98, CI 95% 1.16–42.2, P=0.03) and non-metastatic cancer (OR 3.78, CI 95% 1.20–11.93, P=0.02) were the principal mortality predictors. Alcoholism (OR 7.80, CI 95% 1.20–17.50, P<0.001), high SOFA scores (OR 1.44, CI 95% 1.20–1.75, P=0.001) and the isolation of “high risk” organisms including Pseudomonas aeruginosa, Acinetobacter spp, Stenotrophomonas spp and methicillin resistant Staphylococcus aureus (OR 4.79, CI 95% 1.43–16.03, P=0.01), were associated with increased mortality in ventilator-associated pneumonia. The use of non-invasive ventilation was independently protective against mortality for patients with community-acquired and hospital-acquired pneumonia (OR 0.35, CI 95% 0.18–0.68, P=0.002). Mortality was similar for patients requiring both invasive and non-invasive ventilation and non-invasive ventilation alone (21% compared with 20% respectively, P=0.56). Pneumonia risks and mortality predictors in Australian and New Zealand ICUs vary with pneumonia type. A history of alcoholism is a major risk factor for mortality in ventilator-associated pneumonia, greater in magnitude than the mortality effect of immunosuppression in hospital-acquired pneumonia or community-acquired pneumonia. Non-invasive ventilation is associated with reduced ICU mortality. Clinical signs of consolidation worsen, while rationalising antibiotic therapy within three days of ICU admission improves mortality for community-acquired pneumonia patients.

APA, Harvard, Vancouver, ISO, and other styles

27

Willson, Grant. "Non-invasive weaning from ventilation reduces mortality, ventilator-associated pneumonia, and length of stay in intubated adults." Australian Journal of Physiotherapy 55, no. 3 (2009): 207. http://dx.doi.org/10.1016/s0004-9514(09)70083-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Contal, Olivier. "CR 12 – Réentraînement à l’effort sous ventilation non invasive de l’insuffisant respiratoire." Kinésithérapie, la Revue 16, no. 170 (February 2016): 30. http://dx.doi.org/10.1016/j.kine.2015.11.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

da Cunha Macedo Conde, Mariana, Pablo Safwat Bayoumy Delis, Peter J Papadakos, and Antonio M. Esquinas. "Ocular disorders in non-invasive ventilation and CPAP therapy—A case report." Canadian Journal of Respiratory Therapy 58 (September 20, 2022): 143–45. http://dx.doi.org/10.29390/cjrt-2022-020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Sarc, Irena, Kristina Ziherl, and Antonio M. Esquinas. "Non‐invasive ventilation versus oxygen therapy in cystic fibrosis: Long‐term effects." Respirology 24, no. 12 (October 11, 2019): 1222. http://dx.doi.org/10.1111/resp.13709.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Harb, Hadeer S., Haitham Saeed, Yasmin M. Madney, Mona A. Abdelrahman, Hasnaa Osama, Antonio M. Esquinas, and Mohamed E. A. Abdelrahim. "Update efficacy of aerosol therapy with noninvasive ventilator approach (non-invasive ventilation and nasal high flow)." Journal of Drug Delivery Science and Technology 59 (October 2020): 101922. http://dx.doi.org/10.1016/j.jddst.2020.101922.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Kremeier, P. "The COVID-19 Pandemic as a Stress Test – ensuring Individual Medical Respiratory Care: Aspects to Objectify the Discussion." Clinical Social Work and Health Intervention 12, no. 2 (June 30, 2021): 63–67. http://dx.doi.org/10.22359/cswhi_12_2_12.

Full text

Abstract:

The COVID-19 pandemic confronts intensive care medicine with a new clinical picture, which is manifested in various forms and which clearly differs from the classic acute respiratory distress syndrome (ARDS). Ventilation therapy for COVID-19 pneumonia is complex and, contrary to previous guidelines for the treatment of acute respiratory failure, an increasing number of these patients do not primarily receive invasive ventilation. High-flow O2 therapy and non-invasive ventilation by mask or ventilation helmet have become key treatment options. In endeavours to provide respiratory care to all segments of the population whenever necessary, other therapeutic devices may be employed. The fact that milder cases of these diseases can also be treated with less expensive out-of-hospital ventilators and HFOT devices and that a full-fledged intensive care ventilator may not be imperative must be considered in the final decision. Nevertheless, answers to the triage and allocation of ventilators must be found in a discussion involving society as a whole and the health sciences in particular. The health sciences are called upon to contribute to the public debate on the distribution of all necessary resources during the pandemic.

APA, Harvard, Vancouver, ISO, and other styles

33

Potapova, Natalya L., and Inessa N. Gaymolenko. "Acoustic assessment of pulmonary ventilation in children with bronchial asthma on the background of a single exposure to microwave radiation." Pediatrician (St. Petersburg) 11, no. 3 (August 19, 2020): 65–72. http://dx.doi.org/10.17816/ped11365-72.

Full text

Abstract:

Summary. Diseases of the respiratory organs of children, occurring with obstructive syndrome, represent one of the most serious problems in terms of transition to chronic forms. The chronic process is accompanied by a decrease in pulmonary ventilation, which leads to the search for effective methods of complex therapy of diseases. The purpose of this study was to evaluate the dynamics of acoustic indicators of pulmonary ventilation in children with bronchial asthma, against the background of non-invasive non-thermal microwave radiation. Materials and methods. 122 children with bronchial asthma aged from 3 to 17 years were examined. 113 patients underwent a single session of non-invasive microwave therapy with the Aster device. Comparison of acoustic characteristics of pulmonary ventilation was carried out taking into account the severity of the disease and the age of children with bronchial asthma. Acoustic assessment of ventilation function was performed using the computer bronchophonography complex Pattern-01 before the Aster procedure, after 5 and 15 minutes. In 20 (16.4%) patients with bronchial asthma, the dynamics of cough was evaluated against the background of Aster therapy for 7 days. Results. Improvement of bronchial patency was registered in all age groups with mild bronchial asthma. In the group of moderate asthma, exposure to electromagnetic radiation led to a significant reduction in ventilation disorders in children aged 711 years. As patients grow older, as well as with severe bronchial asthma, the smallest dynamics of the parameters of pulmonary ventilation was observed against the background of Aster therapy. The use of electromagnetic radiation in addition to traditional basic therapy for 7 days leads to a faster regression of cough in patients with bronchial asthma. Conclusion. The combination of traditional basic therapy with electromagnetic non-thermal radiation in patients with bronchial asthma reduces obstructive pulmonary ventilation disorders and promotes faster cough regression.

APA, Harvard, Vancouver, ISO, and other styles

34

Moerman, Damien, Grégory Reychler, Pascal Matte, Thierry Detaille, Stéphan Clément de Cléty, and Laurent Houtekie. "Aérosolthérapie et ventilation non invasive avec fuite intentionnelle en pédiatrie : étude in vitro." Kinésithérapie, la Revue 13, no. 137 (May 2013): 38–43. http://dx.doi.org/10.1016/j.kine.2012.10.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Biazus, Graziela Ferreira, and Cidia Cristina Kupke. "Clinical profile of newborns undergoing physical therapy in a neonatal intensive care unit." Fisioterapia em Movimento 29, no. 3 (September 2016): 553–60. http://dx.doi.org/10.1590/1980-5918.029.003.ao13.

Full text

Abstract:

Abstract Introduction: In neonatal therapy units, physical therapy is directed toward integral baby care. Objective: To describe the profile of newborns (NBs) hospitalized in a Neonatal Intensive Care Unit (NICU). Methods: Retrospective documentary study with data collection from medical records from July 2011 to July 2013. The sample consisted of NBs who performed motor and respiratory therapy. Data were grouped into five categories according to birth weight (≤ 1000g, 1001-1500g, 1501-2000g, 2001-2500g, ≥ 2501g). Results: total of 1,884 newborns were admitted to the NICU within the stipulated period, 168 (13.9%) underwent physical therapy. Of the 168 NBs who underwent physical therapy, 137 were born in the hospital (81.5%) and 31 were transferred there (18.5%); 17 of these babies died during the neonatal hospital stay (10.1%). All newborns of the extremely low birth weight group (≤ 1000g) required mechanical ventilation, 72.7% non-invasive ventilation and 16.6% high-frequency oscillatory ventilation. The occurrence of pneumothorax in the extremely low birth weight group was 13.8% and 16% in the group with birth weight 1001-1500g. Conclusion: Infants with low birth weight (<2500g) constituted the profile of NBs who underwent physical therapy, which was directly related to higher incidence of death and pneumothorax, as well as increased use of mechanical and non-invasive ventilation.

APA, Harvard, Vancouver, ISO, and other styles

36

Milross, Maree A., Amanda J. Piper, Tiffany J. Dwyer, and Peter T. P. Bye. "Non‐invasive ventilation versus oxygen therapy in cystic fibrosis: Long‐term effects – Reply." Respirology 24, no. 12 (October 11, 2019): 1222–23. http://dx.doi.org/10.1111/resp.13708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

McCreesh, Samuel. "Non-invasive ventilation as a prehospital intervention for acute COPD exacerbation." Journal of Paramedic Practice 11, no. 9 (September 2, 2019): 376–80. http://dx.doi.org/10.12968/jpar.2019.11.9.376.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) is the second most common respiratory illness in the UK, affecting over 1 million people. Acute exacerbations of COPD are a common presentation to the ambulance service and account for thousands of hospital admissions annually. Acute respiratory failure accompanies approximately 20% of exacerbations. Current prehospital treatment focuses on oxygen and pharmacological therapy to treat the underlying causes. Non-invasive ventilation (NIV) is a method of ventilatory support that does not require endotracheal intubation, avoiding significant risks associated with intubation and sedation. While some UK ambulance services have introduced NIV, UK guidelines primarily focus on hospital use. International trials have shown prehospital NIV to be more effective than standard treatment in terms of reducing the need for intubation and invasive ventilation in hospital. However, further research is necessary before NIV is introduced widely in UK prehospital paramedic practice.

APA, Harvard, Vancouver, ISO, and other styles

38

Das, Akshaya Kumar, Arushi Gupta, and Niti Dalal. "Effectiveness and safety of non invasive pressure ventilation in severe COVID-19 disease: A retrospective analysis." Panacea Journal of Medical Sciences 11, no. 2 (August 15, 2021): 209–15. http://dx.doi.org/10.18231/j.pjms.2021.045.

Full text

Abstract:

Noninvasive ventilation (NIV) has a controversial role in treating acute hypoxemic respiratory failure in Severe COVID-19 disease. Noninvasive ventilation has been known to avoid intubation and prevent complications associated with mechanical ventilation, but the risk of aerosolization and consequent contraction of disease deterred clinicians from using it.: The medical records of 18 patients having severe COVID -19 disease with Acute respiratory distress syndrome (ARDS), who received NIV therapy in a tertiary care hospital were scrutinized from a period of 15 June 2020 to 28 June 2020. The parameters like respiratory rate (RR)and PaO2/FiO2(PF ratio) and SOFA score were collected from the day of admission to 5th day of ICU stay. Other parameters like outcomes of NIV therapy, complications and time taken from weaning from NIV were recorded. Forty-five health care workers, involved in the treatment were educated about use of PPE and NIV and were tested for COVID -19 by RT-PCR post-ICU rotation.: The statistical analysis was done by statistical package for social science version(SPSS) 22.0. The parameters were compared by using repeated measure analysis of variance.The mean age group of the patient in the study was 47.44 years. The respiratory rate and PaO2/FIO2 at the time of ICU admission were 29.28±3.74 per minute and 121.06±29.05 respectively. There was significant improvement in PF ratio throughout the observation (p=0.021) and the respiratory rate decreased after NIV therapy from the day of admission to the subsequent days (p=0.001). The major proportion (i.e. 88.8%) of patients with ARDS but SOFA score <5, had a favorable outcome with NIV therapy. 45 HCWs tested negative for SARS-CoV-2. Non-invasive ventilation can be safely used as an effective therapy for moderate to severe ARDS due to COVID-19 disease.

APA, Harvard, Vancouver, ISO, and other styles

39

Angliss, M., M. Leclerc, and S. Jackman. "P004 Non-Invasive Ventilation - Partnering with Paediatric NDIS participants and their families." SLEEP Advances 2, Supplement_1 (October 1, 2021): A23. http://dx.doi.org/10.1093/sleepadvances/zpab014.053.

Full text

Abstract:

Abstract To discuss a new funding pathway for Non-Invasive ventilation (NIV) in Paediatrics. Since October 2019, the National Disability Insurance Scheme (NDIS) introduced funding for NDIS participants in the category ‘Disability-related Health Supports - Respiratory Support’. From August 2020, a nursing project was funded by the Hospital Executive to facilitate the transfer of NIV consumable costs to the NDIS. A retrospective review of 256 NIV patients (Bi-Level Positive Airway Pressure (BiPAP) and Continuous Positive Airway Pressure (CPAP)) and the patients NDIS eligibility status. 110 patients were identified as potential NDIS eligible patients by Primary diagnosis and their families contacted and supported to access NDIS funding for NIV device and consumables. By May 2021, 163 patients were NDIS participants on NIV therapy. Formal Assistive Technology (Respiratory ventilation) requests were developed with Key stakeholder input and supplier quotes obtained for machines and consumables. Nursing support, whilst labour intensive has shown to benefit Paediatric patients and their families accessing NDIS funding for NIV therapy in the future. Furthermore, the purchasing of disability-related health supports through NDIS funding is an alternative funding model for NIV in Paediatrics.

APA, Harvard, Vancouver, ISO, and other styles

40

Inal-Ince, Deniz, Sema Savci, Arzu Topeli, and Hulya Arikan. "Active cycle of breathing techniques in non-invasive ventilation for acute hypercapnic respiratory failure." Australian Journal of Physiotherapy 50, no. 2 (2004): 67–73. http://dx.doi.org/10.1016/s0004-9514(14)60098-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Jeganathan, Vishnu, Linda Rautela, Simon Conti, Krisha Saravanan, Alyssa Rigoni, Marnie Graco, Liam M. Hannan, Mark E. Howard, and David J. Berlowitz. "Typical within and between person variability in non-invasive ventilator derived variables among clinically stable, long-term users." BMJ Open Respiratory Research 8, no. 1 (March 2021): e000824. http://dx.doi.org/10.1136/bmjresp-2020-000824.

Full text

Abstract:

BackgroundDespite increasing capacity to remotely monitor non-invasive ventilation (NIV), how remote data varies from day to day and person to person is poorly described.MethodsSingle-centre, 2-month, prospective study of clinically stable adults on long-term NIV which aimed to document NIV-device variability. Participants were switched to a ventilator with tele-monitoring capabilities. Ventilation settings and masking were not altered. Raw, extensible markup language data files were provided directly from Philips Respironics (EncoreAnywhere). A nested analysis of variance was conducted on each ventilator variable to apportion the relative variation between and within participants.ResultsTwenty-nine people were recruited (four withdrew, one had insufficient data for analyses; 1364 days of data). Mean age was 54.0 years (SD 18.4), 58.3% male with body mass index of 37.0 kg/m2 (13.7). Mean adherence was 8.53 (2.23) hours/day and all participants had adherence >4 hours/day. Variance in ventilator-derived indices was predominantly driven by differences between participants; usage (61% between vs 39% within), Apnoea–Hypopnoea Index (71% vs 29%), unintentional (64% vs 36%) and total leak (83% vs 17%), tidal volume (93% vs 7%), minute ventilation (92% vs 8%), respiratory rate (92% vs 8%) and percentage of triggered breaths (93% vs 7%).InterpretationIn this clinically stable cohort, all device-derived indices were more varied between users than the day-to-day variation within individuals. We speculate that normative ranges and thresholds for clinical intervention need to be individualised, and further research is necessary to determine the clinically important relationships between clinician targets for therapy and patient-reported outcomes.

APA, Harvard, Vancouver, ISO, and other styles

42

Patel, Shahid M., Girija P. Nair, Balaji G. Tuppekar, and Abhay G. Uppe. "Effectiveness of non-invasive ventilation in patients with type 2 respiratory failure." International Journal of Research in Medical Sciences 9, no. 3 (February 25, 2021): 794. http://dx.doi.org/10.18203/2320-6012.ijrms20210880.

Full text

Abstract:

Background: Assess the use of non-invasive ventilation as an alternative way for ventilation in acute respiratory failure, determine factors that can predict the successful use of NIV, evaluate factors hindering success of NIV.Methods: Thirty hospitalised patients fulfilling inclusion criteria, diagnosed with Type II Respiratory Failure on ABG were recruited after obtaining an informed written consent. Complete history and detailed physical examination were followed by routine investigations.Results: Comparison of the pH on admission with the pH after 1st hour of NIV, the latter showed statistically significant improvement. Drop in PaCo2 and rise in PaO2 on ABG from admission and after stopping NIV was statistically significant. Patients with lower MMRC grade and severe cough showed significant improvement in pH, however patient with higher emergency visits and past hospitalisation showed less improvement in pH, after 1 hour of NIV therapy. A total 4 patients were intubated, with mean pH of 7.22, 3 out of them had higher emergency visits, 2 out of them had ICU admission.Conclusions: NIV treatment for COPD with type II respiratory failure avoids intubation, reduces complications and should be considered as first line therapy instead of ET intubation. Lower mMRC grade, lesser hospitalizations, lesser emergency visits, higher BMI, symptoms like cough, can have a positive predictive value for the outcome of NIV.

APA, Harvard, Vancouver, ISO, and other styles

43

Dmitrović, Radmila, Biljana Lazović, and Isidora Simonović. "High flow nasal oxygen therapy (HFNO) in opposition to non-invasive mechanical ventilation (NIV): Advantages, disadvantages and their use in COVID-19 infection: Brief review." Sanamed 16, no. 3 (2021): 227–30. http://dx.doi.org/10.24125/sanamed.v16i3.526.

Full text

Abstract:

In the last few decades, different devices for oxygen application have become available, such as low flow systems, high flow systems (HFNO), and non-invasive ventilation (NIV). They are widely applicable and have many advantages as well as disadvantages. HFNO modalities decrease dead space, improve alveolar ventilation, and apply oxygen up to 60 l/min, delivering it humidified and heated opposite NIV, which increases anatomical dead space, maintains adequate minute ventilation, and is used in more conditions than HFNO, etc. In our research, we included 12 articles. The study was conducted using literature published up from 2013 to July 2020. In our research we used following keywords: 'non-invasive ventilation', 'high-flow nasal oxygen', 'advantages', 'disadvantages', 'COVID-19'. The HFNO system appears to be more successful than standard oxygen treatment and non-inferior to NIV. It is simple, easy to apply but still insufficiently researched. More research is needed in the future on the benefits and disadvantages of the HFNO system.

APA, Harvard, Vancouver, ISO, and other styles

44

Liu, Dongli, Xiaolong He, Jianquan Gao, Qiangqiang Luan, and Yanling Du. "Effect of non-invasive ventilator in combination with tiotropium bromide on pulmonary function and sleep quality of patients with chronic obstructive pulmonary disease complicated with obstructive sleep apnea-hypopnea syndrome." Tropical Journal of Pharmaceutical Research 21, no. 5 (June 19, 2022): 1087–93. http://dx.doi.org/10.4314/tjpr.v21i5.25.

Full text

Abstract:

Purpose: To study the influence of non-invasive ventilator and tiotropium bromide on pulmonary function and sleep quality of patients with chronic obstructive pulmonary disease (COPD) combined with obstructive sleep apnea-hypopnea syndrome (OSAHS).Methods: One hundred and twenty patients with COPD-OSAHS were selected and randomly assigned to control group (CG) and treatment group (TG), with 60 subjects in each group. Non-invasive ventilator therapy was used in both groups, based on conventional therapy, while tiotropium bromide was added in TG. Treatment effectiveness in the two groups was evaluated and compared.Results: Total effectiveness was significantly higher in TG than in CG. Post-therapy arterial oxygen saturation (SaO2) and oxygen partial pressure (PaO2) were increased, while partial pressure of carbon dioxide (PaCO2) and lactic acid (Lac) were decreased in both groups (p < 0.05). Post-treatment values of indices of lung function, viz, forced expiratory volume (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio were higher than the corresponding pre-treatment levels, and also values were significantly higher in TG than in CG (p < 0.05). Average sleep time, apnea and hypopnea index (AHI) and mechanical ventilation time of TG were less than those of CG. There were lower levels of Creactive protein (CRP), procalcitonin (PCT) and interleukin-17 (IL-17) in TG than in CG. During the treatment, no obvious adverse reaction was seen in both groups.Conclusion: Non-invasive ventilator, in combination with tiotropium bromide, is more effective in the treatment of COPD-OSAHS than the use of non-invasive ventilator alone. However, further clinical trials are required before its adoption in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

45

Bautin, A. E., S. N. Avdeev, A. A. Seyliev, M. V. Shvechkova, Z. M. Merzhoeva, N. V. Trushenko, A. P. Semenov, K. B. Lapshin, and O. A. Rozenberg. "Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia." Tuberculosis and Lung Diseases 98, no. 9 (October 26, 2020): 6–12. http://dx.doi.org/10.21292/2075-1230-2020-98-9-6-12.

Full text

Abstract:

The objective: to evaluate the effectiveness of inhaled surfactant therapy in the integrated treatment of severe COVID-19 pneumonia in a multicenter prospective clinical trial of surfactant-BL.Subjects and methods. 122 patients with severe COVID-19-associated pneumonia treated in two treatment centers were enrolled in the study. All of them received antiviral, anticoagulant and anti-inflammatory therapy. 56 patients also received inhalation therapy with surfactant-BL (OOO Biosurf, St. Petersburg, Russia) at a dose of 1 mg/kg 2-3 times a day. The remaining 66 patients received no surfactant-BL inhalation. When included into the study, all patients were divided into two groups based on severity of the condition at the time of inclusion: 62 people (Group I) needed oxygen inhalation through a face mask with the flow of 6-8 L/min for hypoxemia correction (27 received surfactant therapy and 35 did not); other 60 patients (Group II) required non-invasive respiratory support (constant positive airway pressure, non-invasive mechanical ventilation, high-flow oxygen therapy), of them 29 received surfactant therapy, while 31 patients did not.Results. In Group I, switching to invasive mechanical ventilation was required for 3/27 (11.1%) patients who received surfactant therapy, and 10/35 (28.6%) who received no surfactant therapy (p = 0.085); lethality made 3/27 (11.1%) and 9/35 (25.7%) (p = 0.131), respectively. In Group II, among those who received surfactant therapy, 5/29 (17.2%) were switched to invasive mechanical ventilation and 18/31 (58.1%) among those who did not receive it (p = 0.001); lethality made 5/29 (17.2%) and 18/31 (58.1%) (p = 0.001), respectively. In the pooled group of 122 patients with severe COVID-19-associated pneumonia, 8 (14.3%) of 56 patients who received surfactant died, and 27 (40.9%) of 66 died among those who did not receive it, (p = 0.001).Conclusion: Inhalation surfactant therapy can reduce the frequency of switching patients to mechanical ventilation and statistically significantly reduce lethality caused by severe pneumonia associated with SARS-CoV-2.

APA, Harvard, Vancouver, ISO, and other styles

46

Daines, Benjamin, Nitish Mittal, Amr Ismail, and Gilbert Berdine. "Survival following initiation of non-invasive ventilation during hospitalization for chronic hypercapnic respiratory failure." Southwest Respiratory and Critical Care Chronicles 9, no. 37 (January 28, 2021): 40–44. http://dx.doi.org/10.12746/swrccc.v9i37.793.

Full text

Abstract:

Patients hospitalized with chronic hypercapnic respiratory failure often have comorbidities and are at increased risk for mortality after discharge. Non-invasive ventilation (NIV) has become a common therapy for these patients to improve gas exchange both while hospitalized and after discharge. To understand the survival of hypercapnic respiratory failure patients started on home NIV therapy, a prospective study was conducted analyzing rate of survival and predictors of mortality. Patients had a significant one-year mortality rate of 16.7% ± 0.71%. Analysis of demographic and physiologic data revealed that the only significant predictor of mortality was hours of NIV use per day, with greater use associated with increased mortality. Although initial results indicate that NIV can be an effective long term therapy for chronic hypercapnic respiratory failure, these patients remain at high risk of mortality and require regular monitoring. Continued study will increase this cohort and follow it for longer periods of time to better understand the predictors of mortality in patients hospitalized with chronic hypercapnic respiratory failure. Key words: Obesity hypoventilation syndrome, noninvasive ventilation, hypercapnic respiratory failure

APA, Harvard, Vancouver, ISO, and other styles

47

Schmitt, Felix C. F., Daniel Gruneberg, Niko R. E. Schneider, Jan-Ole Fögeling, Moritz Leucht, Felix Herth, Michael R. Preusch, et al. "Non-Invasive Ventilation as a Therapy Option for Acute Exacerbations of Chronic Obstructive Pulmonary Disease and Acute Cardiopulmonary Oedema in Emergency Medical Services." Journal of Clinical Medicine 11, no. 9 (April 29, 2022): 2504. http://dx.doi.org/10.3390/jcm11092504.

Full text

Abstract:

In this observational prospective multicenter study conducted between October 2016 and October 2018, we tested the hypothesis that the use of prehospital non-invasive ventilation (phNIV) to treat patients with acute respiratory insufficiency (ARI) caused by severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and acute cardiopulmonary oedema (ACPE) is effective, time-efficient and safe. The data were collected at four different physician response units and three admitting hospitals in a German EMS system. Patients with respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease and acute cardiopulmonary oedema were enrolled. A total of 545 patients were eligible for the final analysis. Patients were treated with oxygen supplementation, non-invasive ventilation or invasive mechanical ventilation. The primary outcomes were defined as changes in the clinical parameters and the in-hospital course. The secondary outcomes included time efficiency, peri-interventional complications, treatment failure rate, and side-effects. Oxygenation under phNIV improved equally to endotracheal intubation (ETI), and more effectively in comparison to standard oxygen therapy (SOT) (paO2 SOT vs. non-invasive ventilation (NIV) vs. ETI: 82 mmHg vs. 125 mmHg vs. 135 mmHg, p-value SOT vs. NIV < 0.0001). In a matched subgroup analysis phNIV was accompanied by a reduced time of mechanical ventilation (phNIV: 1.8 d vs. ETI: 4.2 d) and a shortened length of stay at the intensive care unit (3.4 d vs. 5.8 d). The data support the hypothesis that the treatment of severe AECOPD/ACPE-induced ARI using prehospital NIV is effective, time efficient and safe. Compared to ETI, a matched comparison supports the hypothesis that prehospital implementation of NIV may provide benefits for an in-hospital course.

APA, Harvard, Vancouver, ISO, and other styles

48

Wollsching-Strobel, Maximilian, Iris Anna Bauer, Johannes Julian Baur, Daniel Sebastian Majorski, Friederike Sophie Magnet, Jan Hendrik Storre, Wolfram Windisch, and Sarah Bettina Schwarz. "The Impact of Non-Invasive Ventilation on Sleep Quality in COPD Patients." Journal of Clinical Medicine 11, no. 18 (September 19, 2022): 5483. http://dx.doi.org/10.3390/jcm11185483.

Full text

Abstract:

Background: Non-invasive ventilation (NIV) has been shown to be the most appropriate therapy for COPD patients with chronic respiratory failure. While physiological parameters and long-term outcome frequently serve as primary outcomes, very few studies have primarily addressed the impact of NIV initiation on sleep quality in COPD. Methods: This single-center prospective cohort study comprised NIV-naïve patients with COPD. All patients underwent polysomnographic evaluation both at baseline and at 3 months follow-up, accompanied by the assessment of health-related quality of life (HRQL) using the Severe Respiratory Insufficiency Questionnaire (SRI) and the Epworth Sleepiness Scale (ESS). A subgroup evaluation was performed to address the impact of comorbid obstructive sleep apnea syndrome (OSAS). Results: Forty-six patients were enrolled and twenty-five patients completed the follow-up period (66.7 ± 7.4 years). NIV resulted in an increase in slow-wave sleep (+2% (−3.5/7.5), p = 0.465) and rapid eye movement sleep (+2.2% (−1.0/5.4), p = 0.174), although no statistical significance could be detected. ESS (−1.7(−3.6/0.1), p = 0.066) also showed a positive trend. Significant improvements in the Respiratory Disturbance Index (RDI) (−12.6(−23.7/−1.5), p = 0.027), lung function parameters, transcutaneous PCO2 and the SRI summary scale (4.5(0.9/8), p = 0.016) were observed. Conclusion: NIV therapy does not decrease sleep quality and is even capable of improving HRQL, transcutaneous PaCO2, daytime sleepiness and RDI, and the latter especially holds true for patients with comorbid OSAS.

APA, Harvard, Vancouver, ISO, and other styles

49

Neto Silva, Ivo, and Dominique Monnin. "Ventilation non-invasive à pression positive lors d’un œdème aigu du poumon : quelle évidence ?" Kinésithérapie, la Revue 20, no. 220 (April 2020): 19–21. http://dx.doi.org/10.1016/j.kine.2019.08.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Wolfskeil, M., Y. Devriendt, A. Dumoulin, and P. Lormans. "Spontaneous pneumomediastinum in Covid-19 : a case of complete resolution despite invasive positive pressure ventilation." Acta Anaesthesiologica Belgica 72, no. 1 (March 2021): 37–43. http://dx.doi.org/10.56126/72.1.5.

Full text

Abstract:

We present the case of a 65-year-old patient who was admitted to the intensive care unit (ICU) due to Covid-19 respiratory failure. During his hospital stay, he developed a spontaneous pneumomediastinum (SP). To date, there have been few reports of SP associated with Covid-19 and even less is known about the impact of positive pressure ventilation on these patients. Our patient was first treated with high-flow nasal cannula oxygen therapy (HFNC). Because of further respiratory deterioration, he was supported with non-invasive ventilation (NIV). Later, he required intubation and ventilation with invasive positive pressure ventilation. Despite this, a complete spontaneous resolution of the pneumomediastinum was observed 13 days after the initial diagnosis.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Non-invasive ventilation therapy'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles